BRINEURA▼(cerliponase alfa) Additional Risk Minimisation Measures (aRMM)

These materials are intended for healthcare professionals in the UK

You can download additional aRMM materials below:

Dosing and Administration Guide (D&A Guide)

Summary of Product Characteristics (SmPC)

Patient Information Leaflet (PIL)

▼This medicinal product is subject to additional monitoring. Special reporting is required in relation to adverse reactions.

©2024 BioMarin International Ltd.

EUCAN-BRIN-00077

Date Of Preparation May 2024